{
    "pmcid": "8811630",
    "qa_pairs": {
        "How were the biparatopic nanobodies engineered to enhance their binding and neutralization capabilities?": [
            "By genetically linking two nanobodies with a flexible Gly-Ser linker",
            "By fusing them with Fc-moieties for increased half-life",
            "By attaching them to albumin-binding motifs",
            "By incorporating additional disulfide bonds for stability"
        ],
        "What are the main targets of the biparatopic nanobodies NM1267 and NM1268 in the SARS-CoV-2 spike protein?": [
            "Distinct epitopes on the receptor-binding domain (RBD)",
            "The N-terminal domain of the spike protein",
            "The S2 subunit of the spike protein",
            "The membrane protein of the virus"
        ],
        "What future modifications are suggested to enhance the duration of effectiveness of biparatopic nanobodies?": [
            "Fusion to Fc-moieties or albumin-binding motifs",
            "Addition of polyethylene glycol (PEG) chains",
            "Incorporation of lipid nanoparticles",
            "Use of adjuvants to boost immune response"
        ],
        "What was the observed effect of NM1267 and NM1268 on transgenic mice expressing human ACE2 when challenged with SARS-CoV-2 variants?": [
            "Significant reduction in disease progression and mortality",
            "Complete prevention of viral entry into cells",
            "No observable effect on disease progression",
            "Increased susceptibility to SARS-CoV-2 infection"
        ],
        "Which SARS-CoV-2 variants did the biparatopic nanobodies show strong neutralizing capacity against in vitro?": [
            "B.1, B.1.351 (Beta), and B.1.617.2 (Delta)",
            "B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma)",
            "B.1.1.7 (Alpha), B.1.617.2 (Delta), and C.37 (Lambda)",
            "B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.1 (Kappa)"
        ]
    }
}